NASDAQ$CBUS
Cibus Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Cibus reported a net loss of $24.3 million in Q3 2025, with revenue of $615,000 and ongoing progress in strategic cost reductions and commercialization initiatives.
Cibus continued to make commercial and regulatory advances in gene-edited crop traits despite generating limited revenue. The company posted a reduced net loss versus the prior year and remains focused on streamlining operations and expanding strategic partnerships.
- Revenue for Q3 2025 was $615,000, with a net loss of $24.3 million.
- EPS for the quarter was -$0.44.
- Cash and cash equivalents stood at $23.9 million, expected to fund operations into Q2 2026.
- Significant progress reported in global regulatory approvals and commercial partnerships for Rice and Canola traits.
Headline financials
Revenue & EPS history
Cibus · Revenue · Quarterly
$615K
Forward guidance
Cibus remains focused on reducing annual cash usage and advancing its partner-funded programs, aiming for initial LATAM Rice revenue by 2027 and broader commercialization beyond.
Tailwinds
- On track to deliver HT traits to LATAM customers by end of 2025
- Initiated field trials in LATAM for commercial rice programs
- Received initial partner payment in Sustainable Ingredients segment
- Completed pre-commercial pilot runs for biofragrance products
- Streamlined operations including Oberlin facility consolidation
Headwinds
- Continued net losses and low current revenue base
- Relying heavily on future partner funding for sustainable ingredients
- Ongoing need for additional financing to maintain operations past Q2 2026
- No revenue breakout provided by segment or geography this quarter
- Uncertainty remains in global regulatory timelines for commercialization
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
-1.1%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-12.4%
Avg return
30 days after
37%
13 / 35 earnings
Positive
+23.6%
Q4 2019
Best reaction
-25.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -10.3% | — | |
| Q4 2025 | -16.7% | -24.7% | -56.8% | |
| Q3 2025 | -0.8% | +1.6% | +28.8% | |
| Q2 2025 | -3.5% | -11.6% | -7.5% | |
| Q1 2025 | -7.8% | -8.1% | -29.4% | |
| Q4 2024 | -6.4% | -9.6% | -23.7% | |
| Q3 2024 | +14.5% | +15.2% | -8.9% | |
| Q2 2024 | -9.2% | +2.7% | -42.4% | |
| Q1 2024 | +2.2% | +9.5% | -37.5% | |
| Q4 2023 | -0.7% | +2.2% | +7.4% | |
| Q3 2023 | +17.0% | +5.0% | -8.8% | |
| Q2 2023 | -9.7% | -13.8% | -19.8% | |
| Q1 2023 | -3.6% | -8.3% | -15.8% | |
| Q4 2022 | +1.6% | -0.7% | -21.5% | |
| Q3 2022 | -1.4% | -7.7% | +22.5% | |
| Q2 2022 | +12.4% | +4.3% | -11.6% | |
| Q1 2022 | -17.3% | -27.4% | -60.0% | |
| Q4 2021 | -2.8% | -21.3% | -20.6% | |
| Q3 2021 | -7.4% | -9.0% | -41.9% | |
| Q2 2021 | +12.0% | +15.1% | +19.9% | |
| Q1 2021 | +4.6% | +3.3% | -17.4% | |
| Q4 2020 | -25.1% | -24.7% | -35.6% | |
| Q3 2020 | -1.4% | -4.0% | -44.3% | |
| Q2 2020 | -6.6% | +0.2% | -8.3% | |
| Q1 2020 | -15.0% | -9.4% | +27.9% | |
| Q4 2019 | +23.6% | +22.7% | -10.1% | |
| Q3 2019 | -9.7% | -10.2% | -16.3% | |
| Q2 2019 | +2.7% | -13.1% | -23.9% | |
| Q1 2019 | -3.5% | -6.7% | -9.3% | |
| Q4 2018 | +8.3% | +20.0% | +34.0% | |
| Q3 2018 | -2.9% | -4.9% | -22.1% | |
| Q2 2018 | -0.7% | -3.1% | -10.8% | |
| Q1 2018 | +1.9% | +22.1% | +28.1% | |
| Q4 2017 | +6.4% | +18.8% | +16.9% | |
| Q3 2017 | +7.8% | +8.2% | -2.2% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro